{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:31:14Z","timestamp":1790188274260,"version":"4.1.0"},"reference-count":12,"publisher":"American Diabetes Association","issue":"11","license":[{"start":{"date-parts":[[2019,10,21]],"date-time":"2019-10-21T00:00:00Z","timestamp":1571616000000},"content-version":"vor","delay-in-days":34,"URL":"http:\/\/www.diabetesjournals.org\/content\/license"}],"funder":[{"DOI":"10.13039\/100000062","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,11,1]]},"abstract":"<jats:sec>\n                  <jats:title>OBJECTIVE<\/jats:title>\n                  <jats:p>Fixed-ratio combinations of basal insulin plus glucagon-like peptide 1 receptor agonist (GLP-1 RA) allow concomitant administration of two proven complementary injectable therapies for type 2 diabetes. This study investigated switching to a titratable fixed-ratio combination of insulin glargine plus lixisenatide (iGlarLixi) in patients with type 2 diabetes receiving daily or weekly GLP-1 RA therapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                  <jats:p>LixiLan-G, a randomized, open-label, 26-week trial, compared switching to iGlarLixi versus continuing prior GLP-1 RA in patients with type 2 diabetes and HbA1c 7\u20139% (53\u201375 mmol\/mol) taking maximum tolerated doses of a GLP-1 RA daily (60% on liraglutide once daily or exenatide twice daily) or weekly (40% on dulaglutide, exenatide extended release, or albiglutide) with metformin with or without pioglitazone and with or without sodium\u2013glucose cotransporter 2 inhibitors. Adherence to randomized treatment was closely monitored throughout the study.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>iGlarLixi (n = 257) reduced HbA1c more than continued GLP-1 RA therapy (n = 257) from a baseline 7.8% (62 mmol\/mol) in both to 6.7% (50 mmol\/mol) and 7.4% (57 mmol\/mol), respectively, at 26 weeks (least squares mean difference \u22120.6%; P &amp;lt; 0.0001). More iGlarLixi patients achieved HbA1c &amp;lt;7% (53 mmol\/mol) (62% vs. 26%; P &amp;lt; 0.0001) and the composite of HbA1c &amp;lt;7% without documented symptomatic hypoglycemia (&amp;lt;54 mg\/dL). Nausea and vomiting rates as well as numbers of documented symptomatic hypoglycemia events per patient-year were generally low but greater with iGlarLixi versus continued GLP-1 RA therapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>Switching to iGlarLixi improves glucose control for patients with type 2 diabetes insufficiently controlled on a maximum tolerated dose of a GLP-1 RA plus oral antihyperglycemic agents.<\/jats:p>\n               <\/jats:sec>","DOI":"10.2337\/dc19-1357","type":"journal-article","created":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T16:15:12Z","timestamp":1568736912000},"page":"2108-2116","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":84,"title":["Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy: The LixiLan-G Randomized Clinical Trial"],"prefix":"10.2337","volume":"42","clinical-trial-number":[{"clinical-trial-number":"nct02787551","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0492-6698","authenticated-orcid":false,"given":"Lawrence","family":"Blonde","sequence":"first","affiliation":[{"name":"Frank Riddick Diabetes Institute, Department of Endocrinology, Ochsner Medical Center, New Orleans, LA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8324-3275","authenticated-orcid":false,"given":"Julio","family":"Rosenstock","sequence":"additional","affiliation":[{"name":"Dallas Diabetes Research Center at Medical City, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5388-0270","authenticated-orcid":false,"given":"Stefano","family":"Del Prato","sequence":"additional","affiliation":[{"name":"University of Pisa School of Medicine, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4821-0117","authenticated-orcid":false,"given":"Robert","family":"Henry","sequence":"additional","affiliation":[{"name":"University of California, San Diego, and Center for Metabolic Research, Veterans Affairs San Diego Healthcare System, San Diego, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naim","family":"Shehadeh","sequence":"additional","affiliation":[{"name":"Endocrinology, Diabetes, and Metabolism Institute, Rambam Health Care Campus, Haifa, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9486-1255","authenticated-orcid":false,"given":"Juan","family":"Frias","sequence":"additional","affiliation":[{"name":"National Research Institute, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Niemoeller","sequence":"additional","affiliation":[{"name":"Sanofi, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Souhami","sequence":"additional","affiliation":[{"name":"Sanofi, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Ji","sequence":"additional","affiliation":[{"name":"Sanofi, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7706-4585","authenticated-orcid":false,"given":"Vanita R.","family":"Aroda","sequence":"additional","affiliation":[{"name":"MedStar Health Research Institute, Hyattsville, MD"},{"name":"Brigham and Women\u2019s Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2019,9,17]]},"reference":[{"key":"2022031300572436900_B1","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.2337\/dc19-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes\u20142019","volume":"42","author":"American Diabetes Association","year":"2019","journal-title":"Diabetes Care"},{"key":"2022031300572436900_B2","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.2337\/dci18-0033","article-title":"Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"41","author":"Davies","year":"2018","journal-title":"Diabetes Care"},{"key":"2022031300572436900_B3","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1111\/dom.13343","article-title":"Free and fixed-ratio combinations of basal insulin and GLP-1 receptor agonists versus basal insulin intensification in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials","volume":"20","author":"Maiorino","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"2022031300572436900_B4","doi-asserted-by":"crossref","first-page":"e3082","DOI":"10.1002\/dmrr.3082","article-title":"GLP-1 receptor agonist added to insulin versus basal-plus or basal-bolus insulin therapy in type 2 diabetes: a systematic review and meta-analysis","volume":"35","author":"Castellana","year":"2019","journal-title":"Diabetes Metab Res Rev"},{"key":"2022031300572436900_B5","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/nrendo.2012.140","article-title":"GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus","volume":"8","author":"Meier","year":"2012","journal-title":"Nat Rev Endocrinol"},{"key":"2022031300572436900_B6","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.2337\/dc16-1495","article-title":"Efficacy and safety of LixiLan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide in type 2 diabetes inadequately controlled on basal insulin and metformin: the LixiLan-L randomized trial","volume":"39","author":"Aroda","year":"2016","journal-title":"Diabetes Care"},{"key":"2022031300572436900_B7","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.2337\/dc16-0917","article-title":"Benefits of LixiLan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide, versus insulin glargine and lixisenatide monocomponents in type 2 diabetes inadequately controlled on oral agents: the LixiLan-O randomized trial","volume":"39","author":"Rosenstock","year":"2016","journal-title":"Diabetes Care"},{"key":"2022031300572436900_B8","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2337\/dc16-2215","article-title":"Glucose concentrations of less than 3.0 mmol\/L (54 mg\/dL) should be reported in clinical trials: a joint position statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"40","author":"International Hypoglycaemia Study Group","year":"2017","journal-title":"Diabetes Care"},{"key":"2022031300572436900_B9","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s13300-016-0218-3","article-title":"The efficacy of IDegLira (insulin degludec\/liraglutide combination) in adults with type 2 diabetes inadequately controlled with a GLP-1 receptor agonist and oral therapy: DUAL III randomized clinical trial","volume":"8","author":"Linjawi","year":"2017","journal-title":"Diabetes Ther"},{"key":"2022031300572436900_B10","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/dom.12661","article-title":"Effect of adding insulin degludec to treatment in patients with type 2 diabetes inadequately controlled with metformin and liraglutide: a double-blind randomized controlled trial (BEGIN: ADD TO GLP-1 Study)","volume":"18","author":"Aroda","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"2022031300572436900_B11","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2147\/DMSO.S141235","article-title":"Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes","volume":"10","author":"Sikirica","year":"2017","journal-title":"Diabetes Metab Syndr Obes"},{"key":"2022031300572436900_B12","doi-asserted-by":"crossref","first-page":"212283","DOI":"10.7573\/dic.212283","article-title":"A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond","volume":"4","author":"Prasad-Reddy","year":"2015","journal-title":"Drugs Context"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/care.diabetesjournals.org\/syndication\/doi\/10.2337\/dc19-1357","content-type":"unspecified","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/42\/11\/2108\/528299\/dc191357.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/42\/11\/2108\/528299\/dc191357.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,13]],"date-time":"2022-03-13T04:29:49Z","timestamp":1647145789000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/42\/11\/2108\/36347\/Switching-to-iGlarLixi-Versus-Continuing-Daily-or"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,17]]},"references-count":12,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2019,9,17]]},"published-print":{"date-parts":[[2019,11,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc19-1357","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,17]]}}}